DOI QR코드

DOI QR Code

Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer

  • Fang, Hong (Department of Oncological Chemotherapy, Peking University First Hospital) ;
  • Lin, Rong-Yan (Department of Oncological Chemotherapy, Peking University First Hospital) ;
  • Sun, Ming-Xia (Department of Oncological Chemotherapy, Peking University First Hospital) ;
  • Wang, Qian (Department of Oncological Chemotherapy, Peking University First Hospital) ;
  • Zhao, Yu-Liang (Department of Oncological Chemotherapy, Peking University First Hospital) ;
  • Yu, Jing-Lin (Department of Oncological Chemotherapy, Peking University First Hospital) ;
  • Tian, Yan (Department of Oncological Chemotherapy, Peking University First Hospital) ;
  • Wang, Xiao-Yun (Department of Oncological Chemotherapy, Peking University First Hospital)
  • Published : 2015.01.22

Abstract

Objective: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Materials and Methods: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. Efficacy, survival time and adverse reactions were observed. The Kaplan-Meier method was adopted for analysis of survival and Cox regression for associated influencing factors. Results: The patients were followed up until October 31, 2013, and the median follow-up time was 19 months. Of 57 patients, there were 4 (7.0%) with complete remission (CR), 8 (14.0%) with partial remission, 31 (54.4%) with stable disease, and 14 (24.6%) with disease progression. The remission rate was 21.1% and the disease control rate was 75.4%. The median progression-free survival (PFS) time and the median overall survival time were 10 months and 15.2 months. The one-year, two-year and three-year survival rates were 47.4%, 23.3% and 10.0%. Gender and pathological types were the independent risk factors influencing PFS time (P=0.028, P=0.009). Tumor pathological type and early efficacy were independent factors for the prognosis (P=0.018, P=0.000). Adverse reactions were mostly rashes of I~II degree and diarrhea and slightly increasing level of aminopherase. The skin adverse event incidence of III degree or above was 1.8% (1/57) and brain metastasis was foudn in 31.6% (18/57). Conclusions: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy.

References

  1. Chu H, Zhong C, Xue G, et al (2013). Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Oncol Rep, 30, 2311-5.
  2. Di BS, Wei KP, Tian JH, et al (2014). Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced nonsmall cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 3419-24. https://doi.org/10.7314/APJCP.2014.15.8.3419
  3. Fukuoka M, Wu YL, Thongprasert S, et al (2011), Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 29, 2866-74. https://doi.org/10.1200/JCO.2010.33.4235
  4. Guo XD, Wu FL, Chen SB, et al (2012). A clinical study on gemcitabin combined with cisplatin sequential to gefitinib in the treatment of advanced non-small cell lung cancer. Prog Mod Biomed, 12, 1696-8.
  5. Heinermann V, Schukz L, Issel RD (2009). Gemcitabine: a modulator of intracellular nucleotide and deoxynucleeotide metabolism. Scminpncol, 22, 118.
  6. Heukamp LC, Buttner R (2010). molecular diagnostics in lung carcinoma for therapy stratification. Pathologie, 31, 22-28 https://doi.org/10.1007/s00292-009-1241-1
  7. Huang JJ, Ma SX, Hou X, et al (2014). Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in apatient with metastatic non-small cell lung cancer. Chin J Cancer, [Epub ahead of print].
  8. Lee Y, Han JY, Kim HT, et al (2013). Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. J Neurooncol, 115, 95-101. https://doi.org/10.1007/s11060-013-1199-y
  9. Mei Q, Li R, Chen Y, et al (2008). Comparison of GP regimen and gefitinib in first line treatment of Advanced non-small cell lung cancer. Cancer Prev Res, 23, 18-9.
  10. Mok TS, Wu YL, Yu CJ, et al (2009). FAST-ACT: randomized, placeb-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small cell lung cancer. J Clin Oncol, 27, 5080-7. https://doi.org/10.1200/JCO.2008.21.5541
  11. Mill AB, Hoogstrsten B, Staquet M, et al (2011). Reporting results of cancer treatment. Cancer, 47, 207-14.
  12. Ma XL, Tang YQ, Kou YY, et al (2013). Efficacy of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer. J Int Transl Med, 1, 85-9.
  13. Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6. https://doi.org/10.7314/APJCP.2013.14.8.4661
  14. Yu S, Zhang B, Xiang C, et al (2014). Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study. Clin Lung Cancer, [Epub ahead of print].
  15. Scahiotti GV, De Marinis F, Rinnaldi M, et al (2010). Phase II randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol, 20, 4285-91.
  16. Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51 https://doi.org/10.1200/JCO.2007.15.0375

Cited by

  1. Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer vol.11, pp.3, 2017, https://doi.org/10.1080/17476348.2017.1290526